JNJ-64264681   Click here for help

GtoPdb Ligand ID: 12239

Synonyms: compound 13 [PMID: 36314537] | JNJ64264681
Compound class: Synthetic organic
Comment: JNJ-64264681 is an orally bioavailable, covalent Bruton's tyrosine kinase (BTK) inhibitor [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 149.49
Molecular weight 518.63
XLogP 3.93
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)N[C@H]1CCC[C@H]1NC(=O)c1sc2c3c1[nH]c(=O)n(c3ccn2)c1cnc(cc1C)CC(C)C
Isomeric SMILES C=CC(=O)N[C@H]1CCC[C@H]1NC(=O)c1sc2nccc3c2c1[nH]c(=O)n3c1cnc(cc1C)CC(C)C
InChI InChI=1S/C27H30N6O3S/c1-5-21(34)30-17-7-6-8-18(17)31-25(35)24-23-22-19(9-10-28-26(22)37-24)33(27(36)32-23)20-13-29-16(11-14(2)3)12-15(20)4/h5,9-10,12-14,17-18H,1,6-8,11H2,2-4H3,(H,30,34)(H,31,35)(H,32,36)/t17-,18+/m0/s1
InChI Key OPLNLPWGEZNZFL-ZWKOTPCHSA-N
No information available.
Summary of Clinical Use Click here for help
JNJ-64264681 has been advanced to clinical evaluation to determine efficacy against B cell malignancies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03607513 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants Phase 1 Interventional Janssen Research & Development, LLC
NCT04657224 A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Phase 1 Interventional Janssen Research & Development, LLC
NCT04210219 A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Phase 1 Interventional Janssen Research & Development, LLC